ClinicalTrials.gg
CompletedNCT00128531Updated Nov 14, 2007

Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer

A Phase 3 interventional study of leuprolide acetate in Prostate Cancer, sponsored by GP-Pharm. Completed at 28 sites in 9 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-11-14.

Sponsored by GP-Pharm · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing leuprolide in Prostatic Neoplasms — 9 open to participants now, 16 under way, 6 of them phase 3. Leuprolide · Prostatic Neoplasms.

Enrollment
25th of 69
120 · median 77
Started
2005
with 1 other
Phase 3
26 of 70
3 open now
Registered
6th of 70
by date
Lead sponsor
3 of 70
GP-Pharm

Among the 70 studies testing leuprolide in Prostatic Neoplasms, this one is the 25th largest by enrollment of the 69 interventional ones that give a count, is one of 2 that started in 2005, is one of 26 in phase 3, and was the 6th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 70 studies testing leuprolide in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About leuprolide

Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing leuprolide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to look at the efficacy and safety of leuprolide acetate in patients with prostate cancer.

Read the detailed description

Other assessments include evaluation of main leuprolide PK parameters in 12 subjects after administration of 3 doses.

Study Design:

This will be a multi-center, open-label, fixed investigation of six monthly dosages of leuprolide acetate 3.75 mg administered to patients with histologically proven carcinoma of prostate, who might benefit from medical androgen deprivation therapy.

A total of 120 male patients will receive a single, i.m. injection of leuprolide acetate 3.75 mg initially on study day 0 (after baseline assessment) and then monthly (i.e. every 28 days) for five months.

12 of the patients will also have plasma leuprolide levels measured for PK analysis during the first 3 injection periods (PK group). These patients will belong to pre-defined study sites.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Phase III
  • open label
  • multiple dose
  • safety study
  • pharmacokinetic study
  • efficacy study
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males >/= 18 years of age, with proven carcinoma of the prostate, who might benefit from medical androgen deprivation therapy
  • of at least 1 year
  • World Health Organization/ (WHO/ECOG) performance status of 0, 1, or 2
  • Adequate renal function at screening as defined by serum creatinine \</= 1.6 times the (upper limit of normal) for the clinical laboratory
  • Adequate and stable hepatic function as defined by \</= 1.5 times the ULN and transaminases (i.e. , SGPT) \</= 2.5 times the ULN for the clinical laboratory at screening
  • Ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the Investigator and to comply with the requirements of the entire study
  • Signed written prior to inclusion in the study

Exclusion criteria

Exclusion Criteria:

  • Evidence of , in the opinion of the Investigator, taking into account medical history, clinical observations and symptoms
  • Evidence of spinal cord compression, in the opinion of the Investigator, taking into account medical history, clinical observations and symptoms
  • Evidence of severe urinary tract obstruction with threatening urinary retention, in the opinion of the Investigator, taking into account medical history, clinical observations and symptoms
  • Excruciating, severe pain from extensive osseous deposits, in the opinion of the Investigator, taking into account medical history, clinical observations and symptoms
  • Testosterone levels \< 1.5 ng/mL at screening, locally determined at the laboratory of each clinical site
  • Previous cancer systemic therapy such as chemotherapy, immunotherapy (e.g. antibody therapies, tumor-vaccines), biological response modifiers (e.g. cytokines) within 3 months of baseline
  • Previous hormonal therapy for treatment of prostate cancer, such as luteinising hormone-releasing hormone (LHRH) analogues (e.g. Lupron®, Zoladex®, etc.) [no wash-out allowed]
  • Previous treatment with androgen receptor (AR) blockers, such as Casodex®, Fugerel®, Megace®, Androcur® (no wash-out allowed)
  • Previous orchiectomy, adrenalectomy or hypophysectomy
  • Previous prostatic surgery (e.g. radical prostatectomy, transurethral resection of the prostate [TUR-P]) within 2 weeks of baseline
  • Previous local therapy to the primary tumor with a curative attempt other than surgery (external beam radiotherapy, brachytherapy, thermotherapy, cryotherapy) within 2 weeks of baseline
  • Any drug within 5 half-lives of its physiological action or 3 months (whichever is longer) before baseline
  • Administration of 5-alpha-reductase inhibitors (Proscar®, Avodart®, Propecia®) within 3 months before baseline
  • Over-the-counter (OTC) or alternative medical therapies which have an estrogenic or anti-androgenic effect (i.e., PC-SPES, saw palmetto, Glycyrrhiza®, Urinozinc®, dehydroepiandrosterone [DHEA]) within the 3 months before baseline
  • Hematological parameters (RBC, total and differential WBC count, count, , hematocrit) outside 20% of the upper or lower limits of normal (, LLN) for the clinical laboratory at screening
  • Co-existent , according to the Investigator's opinion
  • Uncontrolled congestive heart failure, myocardial infarction or a coronary vascular procedure (e.g. balloon angioplasty, coronary artery bypass graft) or significant symptomatic cardiovascular disease(s) within 6 months before baseline; resting uncontrolled hypertension: (>/= 160/100 mmHg) or symptomatic hypotension within 3 months before baseline
  • Venous thrombosis within 6 months of baseline
  • Insulin-dependent diabetes mellitus
  • History of drug and/or alcohol abuse within 6 months of baseline
  • Serious concomitant illness(es) or disease(s) [e.g., hematological, renal, hepatic, respiratory, endocrine, psychiatric] that may interfere with, or put patients at additional risk for, their ability to receive the treatment outlined in the protocol
  • Patients receiving anticoagulants who have prothrombin and partial thromboplastin times outside of the normal range for the laboratory assays; patients who are on anticoagulation or antiplatelet medications (e.g. dipyridamole, ticlopidine, warfarin derivatives) who are not receiving a stable dose for 3 months before baseline; patients who are receiving warfarin-derivative anticoagulants who do not have an (INR) in the therapeutic range for the clinical indication for which the anticoagulant has been prescribed.
  • Blood donations/losses within 2 months of baseline, apart from previous prostatic surgery patients (see earlier exclusion [9]; please note that these patients should not be included in the pharmacokinetic [PK] group)
  • Known to GnRH, GnRH agonist, including any LHRH analogues, or any of the study formulation
  • History of the following prior to the study:

    • immunization (within 4 weeks of baseline);
    • flu shots (within 2 weeks of baseline);
    • anaphylaxis;
    • skin disease which would interfere with injection site evaluation;
    • dermatographism will be documented at screening and followed up while on treatment.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Efficacy: to determine the proportion of patients achieving castration levels of plasma testosterone (defined as <0.5 ng/mL) 4 weeks after the first administration

  2. to determine the proportion of patients maintaining castration levels of plasma testosterone from week 4 to study end

  3. to determine the proportion of patients showing acute rises in plasma testosterone levels upon repeated dosing from week 4 to study end

  4. Safety: evaluation of the safety of the new formulation based on adverse events (AEs), local tolerability, vital signs, electrocardiograms (ECGs), and clinical parameters

Secondary outcomes

  1. Efficacy: determination of serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), and prostate-specific antigen (PSA) concentrations

  2. World Health Organization/Eastern Cooperative Oncology Group (WHO/ECOG) performance status, bone pain, urinary symptoms and urinary pain after administration

07

Study locations

28 sites
  • Urology Centers of Alabama
    Homewood, Alabama 35209, United States
  • Desert Oasis Cancer Center
    Casa Granda, Arizona 85222, United States
  • Southwest Florida Urologic Associates
    Fort Myers, Florida 33907, United States
  • Advanced Research Institute, Inc.
    New Port Richey, Florida 34652, United States
  • Florida Urology Specialists
    Sarasota, Florida 34237, United States
  • Regional Urology
    Shreveport, Louisiana 71106, United States
  • Lakeside Urology
    St. Joseph, Michigan 49085, United States
  • Hamilton Urology, P.A.
    Hamilton, New Jersey 08690, United States
  • Lawrenceville Urology
    Lawrenceville, New Jersey 08648, United States
  • AccuMed Research Associates
    Garden City, New York 11530, United States
  • Urological Surgeons of Long Island
    Garden City, New York 11530, United States
  • Hudson Valley Urology
    Kingston, New York 12401, United States
  • Hudson Valley Urology
    Poughkeepsie, New York 12601, United States
  • Carolina Urologic Research Center
    Myrtle Beach, South Carolina 29572, United States
  • Urology Associates, PC
    Nashville, Tennessee 37209, United States
  • Department of Urology, Vienna University Medical School
    Vienna, A-1090, Austria
  • Urocentrum Praha
    Prague, 120 00, Czech Republic
  • Urology Department, Hviezdoslavova
    Prague, Czech Republic
  • Charles University, Clinic of Urology
    Praha, Czech Republic
  • Masaryk Hospital, Urology Dept.
    Usti nad Labem, 401 13, Czech Republic
  • Department of Urology, Technical University of Dresden
    Dresden, 01307, Germany
  • Department of Urology, Semmelweis University
    Budapest, H-1082, Hungary
  • Department of Urology, Medical School, University of Pécs
    Pecs, H-7621, Hungary
  • Department of Urology, General Hospital of Bolzano
    Bolzano, 39100, Italy
  • Sexual Medicine Unit and Urology, Università Vita Salute San Raffaele Fondazione Centro San Raffaele del Monte Tabor
    Milan, 20132, Italy
  • Department of Urology, Jessenius Faculty of Medicine, Comenius University
    Martin, Slovakia
  • Institut Català d'Oncologia, Hospital Duran I Reynals, Servicio de Oncologia Medica
    Barcelona, 08907, Spain
  • Royal Free Hospital and School of Medicine
    London, NW3 2QG, United Kingdom
08

References and documents

Publications

  • Marberger M, Kaisary AV, Shore ND, Karlin GS, Savulsky C, Mis R, Leuratti C, Germa JR. Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study. Clin Ther. 2010 Apr;32(4):744-57. doi: 10.1016/j.clinthera.2010.04.013. PubMed 20435244 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2005
First posted
Aug 10, 2005
Start
Sep 2005
CompletionActual
Nov 2007
Last update
Nov 14, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00128531
Lead sponsor
GP-Pharm
First posted
Aug 10, 2005
Start date
Sep 2005
Completion
Nov 2007
Last update
Nov 14, 2007
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide

Start the discussion